ERBB2 and neoplasm: Within tumor cells, we identified a biomarker panel from BL tumors (Fig. 1H) that is predictive of late disease progression on CDK4/6i treatment in patients with HR+/HER2- mBC, which was successfully validated in 2 independent cohorts (Figs. 7 and S7-S10).